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Abstract
Background: Jails are an important venue of HIV care and a place for identification, treatment and referral for care. HIV
infected inmates in the San Francisco County jail are offered antiretroviral treatment (ART), which many take only while in
jail. We evaluated the effect of ART administration in a cohort of jail inmates going in and out of jail over a nine year period.
Methodology/Principal Findings: In this retrospective study, we examined inmates with HIV going in and out of jail. Inmates
were categorized by patterns of ART use: continuous ART - ART both in and out of jail, intermittent ART - ART only in jail; never
on ART - eligible by national guidelines, but refused ART. CD4 and HIV viral load (VL) were compared over time in these groups.
Over a 9 year period, 512 inmates were studied: 388 (76%) on intermittent ART, 79 (15%) on continuous ART and 45(9%) never-
on ART. In a linear mixed model analysis, inmates on intermittent ART were 1.43; 95%CI (1.03, 1.99) times and those never on
ART were 2.89; 95%CI (1.71, 4.87) times more likely to have higher VL than inmates on continuous ART. Furthermore, Inmates
on intermittent ART and never-on ART lost 1.60; 95%CI (1.06, 2.13) and 1.97; 95%CI (0.96, 3.00) more CD4 cells per month,
respectively, compared to continuously treated inmates. The continuous ART inmates gained 0.67CD4 cells/month.
Conclusions/Significance: Continuous ART therapy in jail inmate’s benefits CD4 cell counts and control of VL especially
compared to those who never took ART. Although jail inmates on intermittent ART were more likely to lose CD4 cells and
experience higher VL over time than those on continuous ART, CD4 cell loss was slower in these inmates as compared to
inmates never on ART. Further studies are needed to evaluate whether or not intermittent ART provides some benefit in
outcome if continuous ART is not possible or likely.
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Introduction
In the United States, HIV infection is an important health
problem among jails and prisons [1]. Over 2 million individuals
are incarcerated and a quarter of HIV-infected individuals are
believed to pass through correctional facilities annually [2]. Due to
the high proportion of HIV-infected individuals passing through
correctional facilities, jails and prisons serve as entry points and are
often the most consistent site of HIV care for marginalized
populations [3]. However, HIV care in jails, which are usually
local, county run facilities for persons charged, but not convicted
or serving short sentences, is often minimal because stays are
assumed to be short and a single person may be in and out of jail
many times in a single year.
In the mid 1990’s, HIV/AIDS accounted for the top three
causes of death in the United States [1]. Since the introduction of
potent combination anti-retroviral therapy (ART), a reduction in
AIDS deaths nationally, including inmates in correctional settings,
has been reported [4]. This reduction has been attributed to care
and treatment of HIV-infected individuals in correctional facilities
in accordance with the guidelines of the US Center for Diseases
Control (CDC). According to the guidelines, care and treatment in
correctional facilities includes prophylaxis for opportunistic
infections and directly administered ART [5].
Although HIV care while incarcerated is legally protected, this
guaranteed right to care has significant variations in implemen-
tation and is not ensured once an incarcerated person is released.
Many persons taking ART in jail or prison are unable or unwilling
to continue taking their ART medications outside the correctional
institutional setting. Under these circumstances, whether or not to
start or resume ART while incarcerated is a dilemma. Balancing
concerns about developing resistance to ART and the safety of
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intermittent therapy and unplanned but predictable treatment
interruptions for whatever reason with the high mortality of
untreated HIV/AIDS has been a difficult task for a thoughtful jail
clinician.
To date, few studies have evaluated the effects of antiretroviral
treatment over time among jail inmates [6,7,8]. In these studies,
the lack of continuity of care outside the jails and the high rates of
re-incarceration have been associated with a lower likelihood of
achieving the benefit of ART as measured by surrogate markers
such as a gain in CD4 cell count and suppression of HIV viral load
(VL) [7,8]. These studies were limited by:
a) absence of comparison groups [7,8] such as inmates
continuing treatment outside of jails or inmates never on
treatment; and b) shorter duration of observation (1–2 years).
We conducted a retrospective cohort study of HIV positive
inmates in the San Francisco county jail over a nine year period.
Our study objective was to evaluate the benefit of ART
administered in jails, as measured by its impact on CD4 and VL
over time.
Materials and Methods
Study setting
The San Francisco City and County jail’s Forensic AIDS
Project (FAP) provides HIV counseling and testing services, HIV
related primary care including examinations, diagnostic tests,
prophylaxis for opportunistic infections, and ART [5]. All
medications that are approved by the US FDA for HIV care are
available through the jail pharmacy. HIV care, including
prescription of ART, is guided by published national recommen-
dations from the Department of Health and Human Services and
the Centers for Diseases Control and Prevention. If inmates have a
credible history of taking ART immediately prior to incarceration,
the same drugs are continued on entry to jail until further
evaluation takes place. The HIV Clinician is on call to consult with
the admitting jail clinician regarding the prescription of ART. All
medical care, including ART while in jail, is free and voluntary.
The majority of new or modified ART are written by a single
practitioner (ME), an experienced HIV specialist.
Since 1996, the San Francisco jail health has maintained an
electronic database of the health care of all inmates that includes
documented HIV status and records of all pharmacy, laboratory
and clinician contacts with all inmates. When an inmate is booked
into the jail, he/she receives a series of medical assessments. The
initial intake history and physical findings are recorded by jail
healthcare providers. If an inmate was previously in the jail,
electronic records are retrieved and a history of medical problems
outside the jail is recorded. All reports of medication intake outside
the jail are cross-checked by contacting the dispensing pharmacy
and community providers.
Data collection
This retrospective cohort study was based on a review of the
Forensic AIDS Project database over a nine year period.
Individuals identified and documented as HIV positive during
the period 1996–2005, enrolled in the Forensic Aids Project (FAP);
and in jail more than once were reviewed for inclusion in the
study. All data were collected by one person (NPP) and cross-
checked by a second person (JPT). All data were de-identified and
saved on a password protected file.
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of UCSF. Since the study required
chart review, informed consent was waived.
During the period, 1st January 1996- 31st July 2005, 1439 HIV-
positive inmates were screened for eligibility. The following criteria
were used to enroll the inmate: i) was jailed on at least two separate
occasions during the nine year period; ii) was confirmed HIV-
positive, and iii) was eligible to be offered ART based on FAP’s
criteria which reflected current national guidelines at the time; iv)
had CD4 and HIV RNA levels measured at all follow up visits in
jail; and v) had pharmacy notes, community providers notes, and
triage notes available to corroborate claims of medication intake
outside the jails.
Of 1439 inmates of FAP database screened for eligibility, 739
(51%) did not qualify for inclusion for the following reasons: i) in
jail for very short durations (i.e. less than ten days), or ii) only one
period of incarceration. Of the remaining 700 potentially eligible
inmates, 69 were further excluded due to missing data (i.e.,
laboratory, clinical or pharmacy); and an additional 119 inmates
were excluded who did not qualify for ART initiation either due to
very high CD4 cell count or low VL and lack of symptoms. Thus,
data were analyzed on a final sample of 512 inmates who were
eligible for ART that qualified for inclusion in the study.
Data Analysis
Data were abstracted in Microsoft Access and analyzed in R
version 2.3.1 (open access software). Based on the patterns of
medication intake, the 512 inmates were divided into three groups,
i) intermittent ART group: inmates who took ART while in jail; ii)
continuous ART group: inmates who took ART while in jail and
after release from jail including the time between incarcerations;
iii) never on ART group: inmates who at the time of triage qualified
for ART but declined ART both inside and outside of jail.
Using linear mixed effects models in the three groups of inmates
characterized by ART usage pattern, control of HIV infection was
evaluated by examining the surrogate markers (i.e., VL and CD4
T cell counts). Linear mixed effects models allow the examination
of variables that vary within and between individuals, and also
take the correlation structure arising from information that is
clustered within individuals into account [9,10].
We first fitted a random intercepts model, which supposes a
common association (slope) between CD4 cell counts and variables
such as time or VL [10]. We then allowed the coefficients for the
slopes to vary; this supposes that there is some between-person
variability in the rate of change of CD4 over time, and some
between person variability in the rate of change in VL over time
[10]. The estimation procedure for both the random intercepts
and the random intercepts and slopes models used Restricted
Maximum Likelihood, as this is known to provide better estimates
of standard errors than Maximum Likelihood [10]. Interaction
and polynomial terms were also considered in the model but were
not significant and were therefore not included in the final model.
The estimates of linear mixed effects models are interpreted like
ordinary linear regression models. Referent group for comparison
in models 2a, 2b is the continuous treatment group. Referent
groups for variables Gender are Males and for Ethnicity are
Caucasians.
Changes in CD4 cell counts over time across treatment
groups
The association measure is the mean difference in CD4 cell
count between a treatment category and its reference. To assess
the control of HIV infection in the ART group, we first considered
the immunological outcome CD4 cell counts over time. The
relationship between ART group and CD4 cell counts was
investigated using linear mixed effects models. The possible
confounders included in the model were age, ethnicity, gender,
Antiretroviral Therapy Jail
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baseline CD4 cell count, and log transformed VL. VL was time–
varying, while all other possible confounders were measured at
baseline. Interactions of ART group and time were explored, as
was a term for a polynomial of time (time2), as prior clinical
knowledge suggested that interactions may be relevant.
Using 2807 measurements on the 512 inmates, the best-fitting
model as determined by AIC included an interaction between
ART group and time; the addition of squared-time was not
deemed to be necessary. There was no evidence of between person
variability in the changes in CD4 over time. We therefore report
results from a random intercepts model. The rate of change in
CD4 cell counts result from the inclusion of interactions between
treatment group and time in months into the mean model. The
estimates of the rate of change therefore are derived, for example,
by combining the information from the rate of change amongst
always-treated inmates (a gain of .67 cells) and the interaction of
time with intermittent treatment (a loss of 1.60 cells) resulting in a
net change of a loss of .93 cells.
Changes in VL over time across treatment groups
The association measure is the median multiplicative VL between
the treatment category and its reference. Using linear mixed models,
we also examined log VL across the three ART groups. All models
included age, race/ethnicity, gender, and CD4 cell count (which
varied over time) As described above, we explored whether
including an interaction term between ART group and time, or
random slopes in time, improved the model fit. The interaction and
the polynomial in time were not deemed necessary; however,
allowing for between-person variability in the change in VL over
time (i.e., a random slope) appeared to improve the model fit.
Results
Over a nine year period of observation, the median follow-up
duration for each inmate was 31 months (inter-quartile range: 6
months - 9.5 years). The 512 individuals had a median of 5 jail
stays (range 2–20), and 36% had more than five visits in jail. The
average jail stay length was 104 days (3.5 months) The median age
of the inmates at study entry was 36 years (inter quartile range 19–
66 years) (Table 1). A majority of the participants were African
Americans (51%). Men accounted for 86% of the cohort. Inmates
in the continuous ART group were the oldest. In all three groups
of inmates, CD4 and VL were considered at baseline in jail. More
than three-quarters (76%) of the inmates took intermittent ART;
9.0% refused ART and the remaining 15% took continuous ART
throughout the study period. Using chi-square tests, we tested for
differences amongst three ART groups (TABLE 1). At baseline,
factors that were significant between the three groups are age,
baseline VL (p,0.05). Some other significant factors from table 1
are follow up time in jail, exit CD4, exit VL (p,0.05) Over time,
based on results of final models (Table 2, 3), the factors that were
associated with category of ART included age, gender, ethnicity,
time on treatment, baseline CD4 and baseline VL.
Change in CD4 cell counts over time across treatment
groups
There were strong associations between ART groups with CD4
cell counts and HIV VL over time consistent with the use of
guidelines to offer ART for lower CD4 cell counts and higher VL.
The interaction terms for ART groups and time were significant
for intermittent ART and never on ART groups. (Table 2)
On an average, continuously treated inmates gained an average
adjusted of 0.67 CD4 cells per month. The difference (95% CI) in
the adjusted rate of change in the intermittently treated inmates as
compared to continuously treated inmates was 21.60 (22.13,
21.06), resulting in the intermittent ART group inmates lost CD4
cells at an average adjusted rate of 0.93 cells per month. The
difference (95% CI) in the adjusted rate of change in the never on
ART inmates as compared to continuously treated inmates was
21.97 (23.00, 20.96), so that the never-treated inmates lost CD4
cells at an average adjusted rate of 1.29 cells per month. However,
this difference was not statistically significant. (p = 0.33). At
baseline, the differences in CD4 counts and VL among the three
ART groups were statistically significant (p,0.001; Table 2)
As observed in table 2, significant differences in the rate of
change of treatment groups were observed over time (variables
intermittent* time, never on treatment*time; as indicated by p
Table 1. Characteristics of study participants by treatment pattern: continuous, Intermittent and never on treatment.
Continuous (*N=79) Intermittent (*N=388) Never on treatment (*N=45) P value
Follow-up in jail, median (IQR), months 38.2 (12.1–64.1) 39.5 (11.9–63.3) 26.3 (5.5–40.4) 0.018
Age, median (IQR), Years 37.6 (32.1–42.7) 35.3 (30.6–40.7) 34.9 (29.6–40.0) 0.045
Ethnicity (%)
Caucasian 40.5 39.2 37.8 0.948
African American 49.4 51.3 48.9
Other 10.1 9.5 13.3
Sex (%)
Male 91.1 86.6 73.3 0.086
Females 7.6 11.9 24.4
Transgender 1.3 1.5 1.5
Baseline CD4, median(IQR) 302 (185–448) 321.5(191–463) 309 (183–582) 0.678
Exit CD4, median (IQR) 361 (218–538) 290 (139–428) 261 (137–427) 0.017
Baseline viral load, median (IQR) 795(349–20,780) 7465 (500–40,200) 11260 (2,252–57,260) ,0.001
Exit viral load, median (IQR) 378 (75–4,584) 4,644 (105–32,260) 13,000 (3,247 –72,070) ,0.001
*N = sample size. Baseline CD4 and baseline viral load (VL) refer to the first available CD4 and VL in an inmate; Exit CD4 and Exit VL refer to the last available CD4 and VL
on the inmate. P-values are derived from Kruskal-Wallis or chi-squared tests for continuous and categorical variables, respectively.
doi:10.1371/journal.pone.0007115.t001
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values,0.001). Variable time (months) was significant (p value
,0.007). Further interpreting other significant variables like age in
the models, if we were to compare two inmates who were the same
with respect to treatment group, time since baseline, ethnicity, and
gender but differed in age by 1 year, we would expect the CD4 cell
counts to differ by 0.05 (21.29, 1.38) cells. Furthermore, if we
were to compare two inmates who were the same with respect to
treatment group, time since baseline, ethnicity, and age but of
different gender ( female vs. male), then, we would expect CD4 cell
count to differ by 2.73 (227.77, 33,23) cells.
Figure 1 and Figure 2 illustrates the un-adjusted and adjusted
changes in CD4 cell counts for the three ART groups. In Figure 1,
the CD4 cell counts increase in the continuous ART group and fall
most rapidly in the never on ART inmates. In Figure 1, a
descriptive summary of the data is presented and the VL is not
held constant (unadjusted).
In Figure 2, we have attempted to more clearly illustrate the
effect of each ART group. VL was held constant in deriving these
predicted trajectories (adjusted). The baseline CD4 and the VL
were selected to reflect typical (baseline) values for each of the
ART groups. The estimated course of CD4 cell count over time
predicted by the model for a 30 year old male with a constant VL
is shown. Note the trajectories in each of the ART groups in
Figure 2 are broadly similar to the observed trajectories in Figure 1.
We would not expect these to coincide exactly since VL was held
constant over time in Figure 2, which is not the case in the
unadjusted, descriptive summary of the data shown in Figure 1.
These results suggest that compared to inmates that were on never
on ART, the inmates in the continuous ART group documented
the best response overall in terms of gain in CD4 cells over time,
followed by the inmates in the Intermittent ART group with a
slower rate of loss of CD4 cells over time.
Changes in HIV VL over time across treatment groups
Overall the HIV VL decreased by 6% per year in each of the
three treatment groups. From the model, (Table 3) we can infer
that the VL of intermittent ART inmates was approximately one
and a half times and of never-on ART inmates three times greater
than those on continuous ART. After adjusting for the different
covariate distributions, although there was significant differences
in the change in HIV VL over time between Never on treatment
group and referent continuous treatment group, (2.74 (1.50, 5.00);
p value ,0.001), these differences between intermittent treatment
and continuous treatment group were non significant (1.34 (0.92–
1.96); p value ,0.133).Furthermore, Baseline CD4, Baseline VL,
and CD4 over time, were found to significantly differ between
treatment groups (p,0.05) and a non- significant effect of time was
also observed (0.99(0.98,1.00) p value,0.151).
In figure 3, as in figure 1, the un-adjusted local average observed
trajectories of VL in three treatment groups have been illustrated.
Discussion
This is the first study to examine the effect of ART on a cohort
of HIV infected persons going in and out of a county jail over a
relatively long period of time. Our results indicate that a majority
of inmates (76%) interrupted ART after being released from jail. A
few inmates managed to stay on medications (15%), and a
minority (9%) although eligible for ART never agree to take ART,
whether in or out of jail. Results from linear mixed models suggest
that inmates on intermittent and never on ART reported a loss of
CD4 cells at an average adjusted rate of 0.93 cells and 1.29 cells/
month respectively. In comparison, and as expected, the
continuous ART group gained CD4 cells at an average adjusted
Table 3. Model 2: VL. Multivariate associations between
demographic and clinical characteristics and viral load(VL).
Continuous treatments at study entry are the referent state.
Characteristic Estimate{ (95% CI) p-value
Treatment pattern
Intermittent 1.34(0.92, 1.96) 0.133
Never on treatment 2.74 (1.50, 5.00) 0.001
Time (months) 0.99 (0.98, 1.00) 0.151
Treatment pattern6time
Intermittent6time 1.00 (0.99, 1.02) 0.496
Never-on-treatment6time 1.00 (0.98, 1.03) 0.774
Age 0.98 (0.96, 0.99) 0.006
Gender
Female 1.04 (0.72, 1.51) 0.826
Transgender 1.64 (0.57, 4.72) 0.357
Ethnicity
African American 1.19 (0.93, 1.53) 0.172
Other 0.96 (0.62, 1.49) 0.857
Baseline CD4 1.00 (1.00, 1.00) ,0.001
CD4 1.00 (0.99, 1.00) ,0.001
Baseline viral load{ 3.20 (2.86, 3.57) ,0.001
{Estimates have been back-transformed to reflect a multiplicative change in VL
(i.e., to reflect associated multiplicative changes on the natural scale rather than
additive changes on the log scale)Associationmeasure is themedianmulti-
plicative VL between the treatment category and its referent state.
{VL (log10 scale) is translated by log10 (5,000).
doi:10.1371/journal.pone.0007115.t003
Table 2. Multivariate associations between demographic and
clinical characteristics and CD4 cell count levels. Continuous
treatments at study entry are the referent state. Model 1:
CD4.
Characteristic Estimate (95% CI) p-value
Treatment pattern (baseline mean)
Intermittent 10.18 (220.20, 40.57) 0.512
Never on treatment 30.49 (216.62, 77.59) 0.205
Time (months) 0.67 (0.18, 1.16) 0.007
Treatment pattern6time
Intermittent6time 21.60 (22.13, 21.06) ,0.001
Never-on-treatment6time 21.97 (23.00, 20.94) ,0.001
*Age 0.05 (21.29, 1.38) 0.944
Gender
Female 2.73 (227.77, 33.23) 0.861
Transgender 22.03 (286.31, 82.26) 0.962
Ethnicity
African American 9.63 (211.75, 31.02) 0.378
Other 8.85 (228.07, 45.77) 0.639
Baseline CD4 0.79 (0.75, 0.83) ,0.001
Viral load{ 233.33 (237.82, 228.83) ,0.001
Association measure is the mean difference in CD4 cell counts between a
treatment category and its referent category.
{VL (log10 scale) is translated by log10 (5,000), and is time-varying.
*Age is translated (i.e., subtracted) by 30 years.
doi:10.1371/journal.pone.0007115.t002
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rate of 0.67 cells per month. Similarly, those on intermittent ART
and never on ART reported higher VL (i.e., 1.5 times and 3 times)
in comparison with inmates on continuous ART.
How do our study findings compare with those of
previous studies?
An examination of Table 1 suggests that there were no racial
disparities across ART groups. This is in contrast with data from
previous studies that suggest that African Americans dispropor-
tionately lack adequate care [11,12]. In our study, inmates on
continuous ART were demographically similar to inmates on
intermittent ART. All inmates taking ART were offered the same
standard of care in jails.
In another study by Springer et al, 1866 prison inmates were
followed for mean 478 day period. Twenty-seven percent of re-
incarcerated inmates lost the beneficial effects of ART. However
59% achieved an undetectable HIV VL (VL,400 copies/ml) by
their last visit in prison [7]. In another study on 15 prison inmates
by Stephenson et al., over 38% of re-incarcerated inmates lost the
benefit of ART, with deleterious effects on VL and CD4 after
release over a two year period [8]. In comparison, in our study
encompassed information from a nine year period, with a median
follow up of 31 months (2.6 years), 169 (32.4%) inmates achieved
viral suppression at their last visit in jail. This benefit was present
across both the continuous and intermittent treatment groups.
Some aspects of our study results are pertinent in evaluating the
approach to care and treatment in jailed HIV infected inmates.
Although a majority (76%; 388/512) of inmates were on
intermittent ART demonstrating the difficulty of maintaining
adherence to their HIV medications outside of jail, many inmates
managed to continue their ART over time (15%; 79/512).
Intermittent ART lost CD4 over time, and had higher VL
suggesting loss of beneficial effects of ART compared to
continuous ART. On the other hand, there is a suggestion that
intermittent ART provides some benefit in comparison to never
on ART.
We are concerned about deleterious effects of intermittent
therapy in light of SMART (Strategies for Management of ART)
data and the possibility of the development of resistance [13].
SMART, however, compared only intermittent CD4 cell-guided
ART interruptions with continuous ART [13,14]. The reality of
HIV care for most incarcerated patients at present is intermittent
treatment or no treatment at all. In any jail study, the comparison
of individuals on intermittent ART is further complicated due to
lifestyle factors affecting adherence and co-morbidities. In our
cohort analysis, it is clear that continuous ART is best; however
those who are on intermittent therapy are better off than the never
on ART. Medications must and should be provided, and the
platforms for provision of continuous care outside jails should be
focused on maintaining the benefits of ART after release.
Figure 1. Local average of CD4 counts over time by treatment pattern: intermittent, continuous, and never-on treatment. In the
figure, a Continuous ART inmate is noted with pink plus (dotted line), and Intermittent ART inmate is noted with a gray circle (solid line), and the
yellow triangles (dashed line) mark the Eligible but Never on treatment inmates.
doi:10.1371/journal.pone.0007115.g001
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Our study reflects a true natural history study of a large cohort
of incarcerated HIV-infected persons. It highlights the need to
support continuous ART therapy and the importance of
continuity of care services for HIV infected persons who enter
the cycle of incarceration. Given the recidivism rates of 60%–70%
jail settings must be optimized as intermittent care sites with
seamless connections to community care.
This is the first study in a jail cohort to apply multi-level
analyses. It will be inappropriate to compare this data with a
standard cohort study or a compliant trial population, but it does
raise important questions that should be addressed by prospective
evaluations of similar incarcerated populations. Although ques-
tions on adherence and resistance are compelling, they cannot be
answered in this context, since this study was aimed to be a
preliminary exploration of the natural history of a jail cohort.
Funding future studies on factors associated with staying on
medications outside jail will aid in understanding individual
patient and system issues that impact continuity with ART
outside jails.
Strengths
This large retrospective cohort study spans an observation
period of 9 years, and attempts to evaluate the impact of
antiretroviral treatment in the management of HIV infection over
this long period of time. The effects of ART have been compared
across three groups of inmates characterized by patterns of ART
usage (i.e., intermittent ART, continuous ART, and never on
ART). The size of the inmate cohort is large, and data were
verified from multiple sources (i.e., pharmacy, laboratory,
community providers), increasing confidence in their reliability.
Furthermore, claims of medication intake in the community were
ascertained by linked pharmacy and laboratory records and from
the network of community providers.
Limitations
Our study was limited by the nature of retrospective cohort jail
data available. The study did not address factors that might
predispose to non-adherence or adherence of ART such as
repeated incarceration itself, unstable housing, mental illness, and
drug and alcohol dependency. Categorization into the 3 groups
was based on chart review data that was drawn from multiple
sources. We were unable to examine the development of viral
resistance over time; although it is possible that viral resistance in
the intermittent group was unusual, reflecting the abrupt
discontinuation of ART. It is possible that the never on ART
Group included individuals with low T-cells who did not progress,
thus making them seem healthier. Hospitalization rates were not
measured, nor were concomitant illnesses or mortality rates. We
believe that future studies of this important population would
benefit from analyzing these outcomes.
Figure 2. Expected CD4 over time by for a 30 year-old Caucasian male, as predicted from a linear mixed effects model. Baseline CD4
counts and viral load (VL) over time are taken to reflect the baseline status of the inmates by the pattern of medication intake: CD4 cells at 330 cells/
ml at baseline and a VL of 800 copies/ml for an inmate who was continuously treated; CD4 cells at 330 cells/ml at baseline and a VL of 7,500 copies/ml
for an inmate who was intermittently treated; CD4 cells at 430 cells/ml at baseline and a VL of 8,000 copies/ml for an inmate who was never treated.
doi:10.1371/journal.pone.0007115.g002
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Conclusion
The dual epidemics of incarceration and HIV in the US have
led to a high concentration of HIV -infected individuals in
incarcerated settings [15]. With HIV testing guidelines being
expanded to all populations, it is likely that more HIV infection
will be detected in incarcerated individuals in the future. This
study demonstrates that there is a clear benefit from continuous
ART therapy in a group of persons going in and out of jail on both
CD4 cell counts and VL especially compared to those who refuse
ART despite eligibility by national treatment guidelines. There
was also no clear evidence in this cohort of harmful effects on CD4
and VL for ART therapy taken only in jail. There is a need to
examine ART policies both inside and outside correctional settings
and aim towards the establishment of effective life long
management of HIV infection for persons affected by incarcer-
ation. To maintain the benefit of ART outside jails, effective
community transition and prison release programs that focus on
ART management along with linkages to community providers,
stabilization of housing, and community based support services are
needed [2,16].
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